- 23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
- 23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
- 23andMe Launches New Genetic Reports on Common Forms of Cancer
- 23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
- 23andMe Reports Third Quarter Fiscal 2024 Financial Results
- 23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
- 23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay
- 23andMe to Report FY2024 Third Quarter Financial Results
- 23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
- 23andMe Reports Second Quarter Fiscal 2024 Financial Results
More ▼
Key statistics
As of last trade, 23andMe Holding Co. (ME:NSQ) traded at 0.5272, 31.41% above the 52 week low of 0.4012 set on Mar 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.5224 |
---|---|
High | 0.5494 |
Low | 0.5197 |
Bid | 0.5255 |
Offer | 0.5288 |
Previous close | 0.5104 |
Average volume | 6.75m |
---|---|
Shares outstanding | 482.92m |
Free float | 465.62m |
P/E (TTM) | -- |
Market cap | 246.48m USD |
EPS (TTM) | -1.10 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 17:54 BST.
More ▼